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   Constants and other parameters 
c= 0.00005     Antigenicity of tumor 
s1= 0      Adoptive immunotherapy term, a constant influx 
s2= 96000000     IL-2 therapy term, a constant influx 
 
For small values of s2 we see no change in the tumor; however for large values of s2 we 
see a clearing of the tumor. All constants and parameters were taken from actual 
medical research. If values could not be found they were chosen to fit the patient data 
that could be found. 
 
Fixed Constants: 
 u2=.03 u3=10  r2=.18  
g1=20000000  g2=100000  g3=1000 
a=1  b=0.000000001   
p1=.1245 p2=5  
Abstract 
IL-2 treatments have recently been identified to significantly reduce metastatic 
melanoma tumors and in some cases eliminate them. The problem with these 
treatments is that a set plan of administration varies from patient to patient and 
methods for determining treatment steps are still in the process of being 
developed. Previous research by Asad Usman and colleagues has used a numerical 
technique using MATLAB to decide treatment protocols. This research used the 
MATLAB’€™s built in ode15s function to addresses treatment procedures including 
the starting and stopping of each treatment and the period in between each 
treatment. Building on this data and existing model, my project will explore several 
other numerical techniques such as other stiff solvers and a stepwise solution using 
ode15s to study IL-2 tumors in metastatic melanoma patients. A stability analysis 
will be made using Maple. The fixed points will be found and a Jacobian matrix will 
be used to determine the eigenvalues and create a stability plot for the system.  
Background 
Cancer is a common disease caused by the unregulated growth and proliferation of 
cells. This project focuses on metastatic melanoma which is a skin cancer caused 
by a malignant tumor of melanocytes.  Melanocytes are the body cells that 
produce the dark pigment melanin and are responsible for skin color. Once these 
cells become malignant they will experience metastasis which is when the tumor 
cells bursts and the malignant cells travel to other parts of the body causing the 
infection to spread. Although the mechanisms of cancer are not yet understood, 
several hypotheses have given rise to effective treatments of this unregulated 
growth. One treatment is chemotherapy. Although this method does kill cancer 
cells there are many side effects because it also targets healthy cells causing 
mutations or killing those cells too. Another treatment used is surgery for the 
physical removal of mutant cells; however, these surgeries are very invasive and 
complications can make the disease worse. A new treatment called adoptive 
immunotherapy has been developed and has promising results because it uses the 
body’s own immune system to fight the disease.  Our bodies can respond to low 
levels of precancerous or cancerous cells by recognizing the antigens and marking 
these cells as “invader” cells. Our immune system is then programmed to destroy 
this marked invader substance that is dangerous to the body. When tumors occur, 
our body’s natural response is to activate T-Lymphocytes to destroy them. They 
are activated by the interleukin IL-2. An interleukin is a protein mediator that 
describes molecular messages between white blood cells and is very important in 
adoptive immunotherapy. IL-2 has been artificially produced to stimulate the 
immune systems of cancer patients specifically those with metastatic melanoma. 
IL-2 treats tumors by stimulating the growth of tumor regression cells. Although IL-
2 has been successful in treating metastatic melanoma it also produces toxicity to 
the patient. Because of this treatments need to be highly regulated and often 
involve several doses. Mathematical  modeling is currently being used to try to 
create procedures specific to individual patient’s needs in order to help regulate IL-
2 treatments in order to make them more effective. 
Results 
Conclusions 
1. The Kirschner Model system is a stiff system, therefore the instability 
causes regular built in Matlab solvers to fail.  
2. The ode15s built in Matlab solver along with a relative tolerance function 
can be used to solve the system. 
3. A stepwise solution can also be used along with the ode15s solver to solve 
the system. 
4. The fixed points can be found using Maple. These values can be used to 
calculate a Jacobian matrix to determine the eigenvalues of the system. 
5. The calculated eigenvalues and a phase portrait plot give us information 
about the stability of the system. Further study is needed to understand the 
complete qualitative behavior of the model and the growth of cancer cells.  
Numerical Methods Used for Simulation 
After trying to model the system using the built in MATLAB ode solvers, we 
discovered this system of equations is a stiff system. These stiff systems arise 
from large changes in variables in a short amount of time, and they create a 
stability issue which caused the ode solvers to fail due to the divergence of the 
system. In order to solve this system we added a relative tolerance function to 
the solver, and also used a stepwise solution. A stability analysis was preformed 
to demonstrate the challenges of the system. The six fixed points were 
determined using Maple and a Jacobian matrix was used to find the eigenvalues 
for each point. The eigenvalues help determine the stability of the system. A 
phase portrait was also created using Maple in order to visual the stability 
between each set of two variables. 
 
Jacobian matrix: 
 
  
  
Tumor Model 
The Kirschner model was used to simulate the interactions between three 
parameters, effector cells, x, tumor cells, y, and interleukin IL-2, z. The 
model predicts real situations in cancer patients. With no treatment 3 cases 
can be observed. Low antigenicity, the ability of the cancer cells to bind to 
the T-Lymphocytes, there is a stable state with large tumors. For moderate 
antigenicities there is a large amplitude followed by a stable limit. For high 
antigenicity there is a short amplitude followed by the destruction of the 
tumor. 
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